AngioDynamics Acquires Eximo Medical


October 3, 2019—AngioDynamics, Inc. announced that it has acquired Eximo Medical, Ltd., an early commercial-stage medical device company, and the Eximo 355-nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of contingent consideration related to certain technical and revenue milestones.

According to AngioDynamics, this transaction expands the company’s existing vascular interventions and therapies product portfolio by adding Eximo’s laser technology, which received 510(k) clearance for use in the treatment of peripheral artery disease (PAD). The Eximo technology complements AngioDynamics’ leading thrombus management and venous insufficiency technologies.

AngioDynamics stated in their announcement that Eximo’s laser technology is capable of delivering short, high-powered pulsed-laser energy in 355-nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures. The technology addresses the risk of perforation through tissue selectivity, addresses the risk of embolization to the patient through the availability of aspiration and is indicated to provide treatment for in-stent restenosis.

Additionally, Eximo’s laser technology treats a variety of PAD lesion types both above- and below-the-knee. The technology is a safe, fast, and effective system that clinical studies have shown to be effective in treating lesions ranging from soft plaque to severely calcified, advised AngioDynamics.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.